Status:

COMPLETED

A Study to Collect Data on the Treatment Pattern of Xarelto + Acetylsalicylic Acid in the Routine Clinical Practice in Patients Who Are Suffering From a Condition That Narrows the Blood Vessels Supplying the Heart and / or a Condition That Most Commonly Narrows the Blood Vessel in the Legs

Lead Sponsor:

Bayer

Conditions:

Coronary Artery Disease

Peripheral Artery Disease

Eligibility:

All Genders

18+ years

Brief Summary

The study will focus on effectiveness and safety of rivaroxaban (Xarelto) when given together with acetylsalicylic acid (combination therapy) to patients suffering from coronary artery disease (a cond...

Eligibility Criteria

Inclusion

  • Adult (≥18 years) patient (except Taiwan ≥ 20 years old).
  • Diagnosis of CAD or symptomatic PAD.
  • Treatment according to local marketing authorization, rivaroxaban 2.5 mg \[BID\] plus Acetylsalicylic acid (ASA) 75-100 mg \[OD\] started up to 4 weeks before or after the ICF is signed.
  • Only in those countries with a marketing authorization of rivaroxaban in the Acute Coronary Syndrome (ACS) indication, patients already on rivaroxaban treatment for ACS for more than 4 weeks, who are subsequently fulfilling criteria for CAD, are also allowed to be enrolled.

Exclusion

  • Contra-indications according to the local marketing authorization.
  • Patients who will be treated with chronic anticoagulation therapy other than rivaroxaban 2.5 mg given for CAD/PAD.
  • Participation in an interventional trial.
  • Enrolment in the XATOA study.

Key Trial Info

Start Date :

May 28 2020

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

September 29 2023

Estimated Enrollment :

3189 Patients enrolled

Trial Details

Trial ID

NCT04401761

Start Date

May 28 2020

End Date

September 29 2023

Last Update

October 25 2023

Active Locations (10)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (10 locations)

1

Many Locations

Multiple Locations, Belgium

2

Many Locations

Multiple Locations, China

3

Many Locations

Multiple Locations, Colombia

4

Many Locations

Multiple Locations, Italy